<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>zynex8kex991_1062005.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
                                                                    Exhibit 99.1

[[ZYNEX LOGO]]



FOR IMMEDIATE RELEASE:

               ZYNEX MEDICAL ESTABLISHES $400,000 CREDIT FACILITY
               --------------------------------------------------

LITTLETON, Colo., Oct. 5, 2005 - Zynex Medical Holdings, Inc. (OTCBB: ZYNX), a
provider of pain management systems and electrotherapy products for medical
patients with functional disability, today announced that it has secured a
$400,000 credit facility with Silicon Valley Bank, the primary operating
subsidiary of Silicon Valley Bancshares (NASDAQ: SIVB). The new credit line will
payoff existing obligations and provide additional capital to expand the
Company's sales, marketing and support efforts related to its standard
electrotherapy products and proprietary NeuroMove(TM) Stroke Recovery System.

"We are pleased to  establish  this new credit  facility  and  partnership  with
Silicon Valley Bank," stated Zynex President and Chief Executive  Officer Thomas
Sandgaard.  "This  facility will enable Zynex to  substantially  accelerate  its
sales and marketing  initiatives and the roll-out of our flagship  NeuroMove(TM)
stroke  recovery  product."  "Zynex is a  rapidly  growing  Denver-area  company
addressing a large market opportunity.  We are pleased to play a role in helping
the company meet its objectives and growth plans," said Kevin  Grossman,  Senior
Relationship Manager of Silicon Valley Bank's Boulder Colorado office.

The  NeuroMove(TM)  system increases the functionality of many stroke victims by
teaching the healthy parts of the brain to  compensate  for damaged  areas.  The
NeuroMove(TM),  which is  significantly  more  sensitive  than  most  diagnostic
equipment,   monitors  muscle  activity  and  selects  signals  from  the  brain
indicating  that the patient is  attempting  to move a certain  muscle.  It then
introduces the actual movement through  electrical  stimulation.  Eventually the
connection  between  the  brain  and  muscle  can  often be  reestablished.  The
NeuroMove(TM)  (www.neuromove.com)  also  can  be  used  to  treat  spinal  cord
injuries.

About Zynex

Zynex  Medical  Holdings,  Inc.,  (www.zynexmed.com),   a  leading  provider  of
therapeutic  devices  for  patients  with  functional   disability  through  the
creation,  distribution,  and  marketing of  electrotherapy  devices since 1996,
strives  to uphold  its  mission to  improve  the  quality  of life of  patients
suffering from debilitating pain or illness by providing innovative  technology.
Utilizing a unique combination of  electromyographic  (EMG) technology  combined
with a system of instruction  and  reinforcement,  including  electrical  muscle
stimulation  (EMS), Zynex offers new treatment options to post-stroke and spinal
injury patients.

About Silicon Valley Bank

Silicon Valley Bank provides  diversified  financial services to emerging growth
and mature companies in the technology, life science and private equity markets,
as well as the premium wine industry.  Through its focus on specialized  markets
and extensive  knowledge of the people and business issues driving them, Silicon
Valley Bank provides a level of service and partnership that measurably  impacts
its clients' success.  Founded in 1983 and headquartered in Santa Clara, Calif.,
the company serves more than 10,000 clients around the world through 27 domestic
offices  and two  international  subsidiaries  in the  U.K.  and  India,  and an
extensive network of relationships with venture capitalists in Asia,  Australia,
Europe,  India,  and  Israel.  More  information  on the company can be found at
www.svb.com.

<PAGE>


Safe Harbor Provision
Certain statements in this release are "forward-looking" and as such are subject
to numerous risks and uncertainties.  Actual results may vary significantly from
the results  expressed or implied in such  statements.  Factors that could cause
actual results to materially differ from forward-looking statements include, but
are not limited to, the Company's ability to meet terms and conditions  required
to  obtain  project   financing,   risks  and  delays  associated  with  product
development,  risk of market  acceptance of new products,  technology or product
obsolescence, competitive risks, reliance on development partners and additional
capital needs.

                                      # # #

</TEXT>
</DOCUMENT>
